LINKER-AL2

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Sep 13, 2024 → Oct 24, 2026

Cited window

Sep 13, 2024 → Sep 3, 2026

Retrieved

Nov 1, 2026

Title

A Phase 1/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain Amyloidosis

Registry

NCT06292780

Study IDs

R5458-ONC-2274 · 2023-507809-34-00

Sponsor

Regeneron Pharmaceuticals

Design

Phase 1/Phase 2 · Interventional, non randomized, sequential

Status

Recruiting

Enrollment

220 estimated

Registered

2024-03-05

Start

2024-08-07 actual

Primary completion

2028-08-20 estimated

Primary endpoint

Incidence of dose-limiting toxicity (DLTs)

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a remark on fatal treatment-emergent adverse events during treatment for relapsed or refractory systemic light chain amyloidosis.
• –Not yet captured in this edition: a view on eligibility, treatment burden and recruitment access for investigational alternatives in relapsed or refractory light-chain amyloidosis.
• –Not yet captured in this edition: a view on access to investigational cellular therapy as an alternative for relapsed or refractory AL amyloidosis.
• –Not yet captured in this edition: a view on access constraints and care-team assessment for alternative investigational treatment in relapsed or refractory AL amyloidosis.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –127 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are not a representative sample of HCP opinion. Reposts, repeated summaries and accounts of the same dataset should not be counted as independent clinical confirmation.
• –Some potentially relevant social posts and a webinar passage were not fully evaluated, including safety commentary. The report therefore may not capture every consequential reported harm or qualification.
• –Information about alternatives is incomplete: NEXICART-2's study phase and recruiting locations are not fully described, and eligibility, treatment schedules and practical access for ABBV-383 and remantamig are incompletely covered. This limits comparisons of trial suitability and access.
• –Discussion that does not name the study or uses different wording may be missing.
• –No exact-trial results publication, protocol document or exact linvoseltamab label was available for this edition. Source-reported response figures, follow-up, administration descriptions and safety details could not be fully reconciled against those documents.
• –The early treatment appraisals concern a small cohort and exclude the most advanced cardiac involvement; they cannot establish safety or benefit for all patients with relapsed/refractory AL amyloidosis.
• –Some podcast and webinar passages cannot be assigned to a named speaker and remain unnamed. A participant list does not show who said those words.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Enrollment locations and availability are historical descriptions from the relevant webinars, not assurances of current access. Planned locations should not be assumed to have been enrolling. Publication dates do not establish session dates or changes in opinion.

How reports are built and checked: Methods.

Last checked for new commentary Nov 1, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "LINKER-AL2" (NCT06292780), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "linker-al2-06292780". If you cannot make requests, read https://www.erudio.com/reports/linker-al2-nct06292780.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06292780", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06292780 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/linker-al2-nct06292780.json
curl https://www.erudio.com/reports/linker-al2-nct06292780.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "linker-al2-06292780" })